Skip to content
In English |
En español
National Cancer Institute
at the National Institutes of Health
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Page Options
Email This Document
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
LiveHelp online chat
Popular Resources
Help Using the NCI Clinical Trials Search Form
Learn About Clinical Trials
About NCI's List of Cancer Clinical Trials
NCI Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-5 of 5 for your search:
Drug:
human papillomavirus vaccine V503
Find trials that include:
Any drugs shown
Trial Status:
Closed
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001 AM2)
Phase:
Phase III
Type:
Prevention
Status:
Closed
Age:
16 to 26
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
2007_538
, V503-001, NCT00543543
2.
A Study of V503 in Preadolescents and Adolescents (V503-002)
Phase:
Phase III
Type:
Prevention
Status:
Closed
Age:
9 to 26
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
2009_611
, V503-002, NCT00943722
3.
A Study of V503 Given Concomitantly With Menactra™ and Adacel™ in 11 to 15 Year Olds (V503-005)(COMPLETED)
Phase:
Phase III
Type:
Prevention
Status:
Completed
Age:
11 to 15
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
2009_670
, V503-005, NCT00988884
4.
A Study of V503 Vaccine in Females 12-26 Years of Age Who Have Previously Received GARDASIL™ (V503-006 AM1)
Phase:
Phase III
Type:
Prevention
Status:
Completed
Age:
12 to 26
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
V503-006
, 2010_504, NCT01047345
5.
A Study of the Safety, Tolerability, and Immunogenicity of V503 Administered to 9- to 15-Year-Old Japanese Girls (V503-008)
Phase:
Phase III
Type:
Prevention
Status:
Closed
Age:
9 to 15
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
V503-008
, NCT01254643
Select All on Page
Help with Results
We Can Answer Your Questions
1-800-4-CANCER
LiveHelp Online Chat
NCI Home
Contact Us
Policies
Accessibility
Viewing Files
FOIA
Site Help
Site Map
Other Versions of this Site:
Mobile
|
Español
Follow Us:
Twitter
YouTube
Facebook
RSS
NIH…Turning Discovery Into Health
®
Mobile | Español
Mobile | Español
